Boehringer Ingelheim

Boehringer Ingelheim is described in the material as the world's largest privately held pharmaceutical company, but elsewhere's corpus doesn't profile it directly — it appears mainly through its China partnerships. Per Yunqi Capital reporting, in early 2023 its China drug development unit signed a formal collaboration with 3D-printed drug platform Triastek to apply MED® 3D printing technology to rapid formulation development for new chemical entities, following Triastek's 2021 selection into Boehringer Ingelheim's global opnMe program for poorly soluble drug research . More recently, in April 2026, it announced a clinical collaboration with Zai Lab, a Qiming Venture Partners portfolio company: a Phase Ib/II study combining Zai's DLL3-targeting ADC zocilurtatug pelitecan with Boehringer Ingelheim's DLL3/CD3 T-cell engager obrixtamig in neuroendocrine carcinoma and extensive-stage small cell lung cancer, with Boehringer Ingelheim acting as sponsor and overseeing trial operations . Beyond these deal snapshots, elsewhere's corpus does not cover its founding history, headquarters, or broader business.